Podium to Practice: Chicago 2025 – Melanoma: DYP688

Podium to Practice: Chicago 2025 – Melanoma: DYP688

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Vanessa Bernstein

Icon Chair Speaker

Speakers

Dr. Omid Hamid

Dr. Elaine McWhirter

Studies / Trials Discussed

9509 – A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas.

Studies/trials discussed:

9509 – A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas.
Tagged